Published: September 2025

Last updated: September 2025

From Data to Decisions: Leveraging Statistics to Improve Healthcare Decision-Making

Health economics is an important field not just in the UK but globally. Decision-makers can use it to prioritise resources used in healthcare systems to maximise population health whilst ensuring value for money. Since 1999, the National Institute for Health and Care Excellence (NICE) has been responsible for these decisions in the UK. There is a need to provide these decision-makers with the best possible evidence for new treatments to support well-informed decisions.

The vast majority of health economic modelling is still conducted using Markov models to capture disease progression. However, these models rely on restrictive assumptions that may not accurately capture real-world disease progression. This talk will discuss two examples from a recent publication
where regression modelling was used to improve the health economic model. The first example will cover using a multinomial logistic regression to predict the changes in haemoglobin health states over time in patients with chronic kidney disease. Traditional Markov models assume a fixed disease progression rate which fails to account for patient subgroups and time-varying rates. Regression models enable dynamic transitions based on patient characteristics like age, sex, and baseline haemoglobin levels. This leads to better modelling of disease progression and subsequent decision-making.

The second example will cover using a generalised linear mixed model (GLMM) to estimate drug doses for each haemoglobin health state whilst adjusting for subgroup characteristics. This allows for a more granular approach to cost-effectiveness analysis. Unlike Markov models, which often require simplifying assumptions to capture drug doses, a GLMM better reflects the uncertainty in the target-population.

As real-world evidence and individual patient data (IPD) become more accessible, alongside increasing computational power, statisticians must apply and share advanced modelling approaches. By doing so, we can enhance healthcare decision-making, ultimately leading to better policies and improved population health.

You may also be interested in

Peer-reviewed publication

Clinical Burden and Healthcare Resource Use of Congenital Thrombotic Thrombocytopenic Purpura in England: A Linked Primary and Secondary Care Data Analysis

YHEC authors: Erin Barker, Heather Riley, Monica Garrett
Publication date: May 2026
Journal: British Journal of Haematology

Abstract

Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra rarehaematological disorder. This study aimed to estimate the clinical burden, healthcareresource use (HCRU) and associated costs of cTTP in England using primary...

Peer-reviewed publication

Effects and Costs of a Group-Based Educational Intervention to Reduce Opioid Use in People with Chronic Pain: I-WOTCH RCT

YHEC authors: Joe Moss
Publication date: May 2026
Publishers: NIHR
Journal: HTA

Abstract

BACKGROUND: The long-term use of strong opioids for chronic non-cancer pain puts people at risk of serious harm. OBJECTIVES: To test the effectiveness and cost-effectiveness of a multicomponent intervention targeting...

Peer-reviewed publication

Quantifying the Case for Prevention: Disease Burden and Cost-Effective Interventions in UK

YHEC authors: Matthew Taylor
Publication date: May 2026
Publishers: Oxford Academic
Journal: Journal of Public Health

Abstract

BACKGROUND: Modifiable risks—tobacco use, poor diet, alcohol consumption, physical inactivity and mental ill-health—drive substantial disease in UK. NICE evidence on preventive interventions targeting these risks and estimates of eligible populations...